EP 2543370 A1 20130109 - Compositions and Methods for Treating Herpes Simplex Virus

Title (en)

Compositions and Methods for Treating Herpes Simplex Virus

Title (de)

Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus

Title (fr)

Compositions et procédés pour traiter le virus de l'herpès simplex

Publication

EP 2543370 A1 20130109 (EN)

Application

EP 11178325 A 20110822

Priority

EP 11176635 A 20110804
US 201113177041 A 20110706
EP 11178325 A 20110822

Abstract (en)

Green tea polyphenol compositions and methods of their use in treating herpes simplex virus (HSV) are provided. Representative green tea polyphenols include, but are not limited to (-)-epigallocatechin-3-gallate as well as green tea polyphenols with one on more ester-linked fatty acids.

IPC 8 full level

A61K 31/353 (2006.01); A61P 31/12 (2006.01); A61P 31/22 (2006.01)

CPC (source: EP)

A61K 31/353 (2013.01); A61K 45/06 (2013.01); A61P 31/12 (2017.12); A61P 31/22 (2017.12)

Citation (applicant)

US 36175211 P
US 6313908 A 20080207
US 2006031120 A1 20060209 - ROEHR DAVID A [US], et al
US 70723405 P 20050811
US 5087445 A 19920211 - HAFFEY JANET G [US], et al
US 5073372 A 19911217 - TURNER DEBORAH J [US], et al
US 5160731 A 19921103 - SABATELLI ANTHONY D [US], et al
US 4522811 A 19850611 - EPPSTEIN DEBORAH A [US], et al
US 4235871 A 19801125 - PAPAHADJOPOULOS DEMETRIOS P [US], et al
US 4501728 A 19850226 - GEHO W BLAIR [US], et al
US 4837028 A 19890606 - ALLEN THERESA M [CA]
US 5019369 A 19910528 - PRESANT CARY A [US], et al
US 4920016 A 19900424 - ALLEN THERESA M [CA], et al
US 4624665 A 19861125 - NUWAYSER ELIE S [US]
US 4655767 A 19870407 - WOODARD JOHN T [US], et al
US 4687481 A 19870818 - NUWAYSER ELIE S [US]
US 4797284 A 19890110 - LOPER ALICE E [US], et al
US 4810499 A 19890307 - NUWAYSER ELIE S [US]
US 4834978 A 19890530 - NUWAYSER ELIE S [US]
US 4877618 A 19891031 - REED JR FRED D [US]
US 4880633 A 19891114 - LOPER ALICE E [US], et al
US 4917895 A 19900417 - LEE EUN S [US], et al
US 4927687 A 19900522 - NUWAYSER ELIE S [US]
US 4956171 A 19900911 - CHANG YUNIK [US]
US 5035894 A 19910730 - LEE CHI-LONG [US], et al
US 5091186 A 19920225 - MIRANDA JESUS [US], et al
US 5163899 A 19921117 - SIBALIS DAN [US]
US 5232702 A 19930803 - PFISTER WILLIAM R [US], et al
US 5234690 A 19930810 - CHIANG CHIA-MING [US], et al
US 5273755 A 19931228 - VENKTRAMA SUBBU S [US], et al
US 5273756 A 19931228 - FALLON RENEE A [US], et al
US 5308625 A 19940503 - WONG OOI [US], et al
US 5356632 A 19941018 - GROSS JOSEPH [IL], et al
US 5358715 A 19941025 - WONG OOI [US], et al
US 5372579 A 19941213 - SIBALIS DAN [US]
US 5421816 A 19950606 - LIPKOVKER LEV M [US]
US 5466465 A 19951114 - ROYDS ROBERT B [US], et al
US 5494680 A 19960227 - PETERSON TIMOTHY A [US]
US 5505958 A 19960409 - BELLO GASTONE P [US], et al
US 5554381 A 19960910 - ROOS ERIC J [US], et al
US 5560922 A 19961001 - CHIEN YIE W [US], et al
US 5585111 A 19961217 - PETERSON TIMOTHY A [US]
US 5656285 A 19970812 - SABLOTSKY STEVEN [US], et al
US 5667798 A 19970916 - ROYDS ROBERT B [US], et al
US 5698217 A 19971216 - WILKING SHARI L [US]
US 5741511 A 19980421 - LEE HUN HAN [KR], et al
US 5747783 A 19980505 - MYUNG SOON-HWAN [KR], et al
US 5770219 A 19980623 - CHIANG CHIA-MING [US], et al
US 5814599 A 19980929 - MITRAGOTRI SAMIR S [US], et al
US 5817332 A 19981006 - URTTI ARTO O [FI], et al
US 5833647 A 19981110 - EDWARDS DAVID A [US]
US 5879322 A 19990309 - LATTIN GARY A [US], et al
US 5906830 A 19990525 - FARINAS KATHLEEN C [US], et al
HARPER, N.J.: "Progress in Drug Research", vol. 4, 1962, article "Drug Latentiation", pages: 221 - 294
MOROZOWICH ET AL.: "Application of Physical Organic Principles to Prodrug Design in E. B. Roche ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs", APHA; ACAD. PHARM. SCI.
"Bioreversible Carriers in Drug in Drug Design, Theory and Application", 1977, APHA
"Design of Prodrugs", 1985, ELSEVIER
WANG ET AL.: "Prodrug approaches to the improved delivery of peptide drug", CURR. PHARM. DESIGN., vol. 5, no. 4, 1999, pages 265 - 287, XP001089610
PAULETTI ET AL.: "Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies", ADV. DRUG. DELIVERY REV., vol. 27, 1997, pages 235 - 256, XP002234351, DOI: doi:10.1016/S0169-409X(97)00045-8
MIZEN ET AL.: "The Use of Esters as Prodrugs for Oral Delivery of (3-Lactam antibiotics", PHARM. BIOTECH., vol. 11, 1998, pages 345 - 365, XP008136253, DOI: doi:10.1007/0-306-47384-4_15
GAIGNAULT ET AL.: "Designing Prodrugs and Bioprecursors I. Carrier Prodrugs", PRACT. MED. CHEM., 1996, pages 671 - 696, XP002290286
M. ASGHARNEJAD: "Transport Processes in Pharmaceutical Systems", 2000, MARCELL DEKKER, article "Improving Oral Drug Transport Via Prodrugs", pages: 185 - 218
BALANT ET AL.: "Prodrugs for the improvement of drug absorption via different routes of administration", EUR. J. DRUG METAB. PHARMACOKINET., vol. 15, no. 2, 1990, pages 143 - 53, XP000653032
BALIMANE, SINKO: "Involvement of multiple transporters in the oral absorption of nucleoside analogues", ADV. DRUG DELIVERY REV., vol. 39, no. 1-3, 1999, pages 183 - 209
BROWNE: "Fosphenytoin (Cerebyx", CLIN. NEUROPHARMACOL., vol. 20, no. 1, 1997, pages 1 - 12, XP009124989, DOI: doi:10.1097/00002826-199702000-00001
BUNDGAARD: "Bioreversible derivatization of drugs--principle and applicability to improve the therapeutic effects of drugs", ARCH. PHARM. CHEMI., vol. 86, no. 1, 1979, pages 1 - 39
FLEISHER ET AL.: "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADV. DRUG DELIVERY REV., vol. 19, no. 2, 1996, pages 115 - 130, XP002478093, DOI: doi:10.1016/0169-409X(95)00103-E
FLEISHER ET AL.: "Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting", METHODS ENZYMOL., vol. 112, 1985, pages 360 - 81, XP008107397
FARQUHAR D ET AL.: "Biologically Reversible Phosphate-Protective Groups", J. PHARM. SCI., vol. 72, no. 3, 1983, pages 324 - 325, XP000650041, DOI: doi:10.1002/jps.2600720332
HAN, H.K. ET AL.: "Targeted prodrug design to optimize drug delivery", AAPS PHARMSCI., vol. 2, no. 1, 2000, pages E6, XP002289540, DOI: doi:10.1208/ps020106
SADZUKA Y.: "Effective prodrug liposome and conversion to active metabolite", CURR DRUG METAB., vol. 1, no. 1, 2000, pages 31 - 48, XP002954303, DOI: doi:10.2174/1389200003339225
D.M. LAMBERT: "Rationale and applications of lipids as prodrug carriers", EUR. J. PHARM. SCI., vol. 11, no. 2, 2000, pages 15 - 27
WANG, W. ET AL.: "Prodrug approaches to the improved delivery of peptide drugs", CURR. PHARM. DES., vol. 5, no. 4, 1999, pages 265 - 87, XP001089610
GARNER, ADVANCED DRUG DELIVERY REVIEWS., vol. 55, 2003, pages 1497 - 1513
FOSTER ET AL., JOURNAL OF VIROLOGICAL METHODS, vol. 75, 1998, pages 151 - 160
WILLARD, JOURNAL OF VIROLOGY, vol. 10, 2002, pages 5220 - 5232
SPEAR ET AL., JOURNAL OF VIROLOGY, vol. 344, 2005, pages 17 - 24
SUBRAMANIAN ET AL., PNAS, vol. 104, no. 8, 2006, pages 2903 - 2908
CARFI ET AL., MOLECULAR CELL., vol. 8, 2001, pages 169 - 179
CARFI ET AL., MOLECULAR CELL, vol. 8, 2001, pages 169 - 179
SHUKLA ET AL., JOURNAL OF CLINICAL INVESTIGATIONS, vol. 108, 2001, pages 503 - 510
MANOJ ET AL., PNAS, vol. 101, no. 34, 2004, pages 12414 - 12421
WHITEBECK ET AL., JOURNAL OF VIROLOGY, vol. 71, no. 8, 1997, pages 6083 - 6093
WILLARD, M., JOURNAL OF VIROLOGY, vol. 10, 2002, pages 5220 - 5232
BEARER ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, vol. 97, no. 14, 2000, pages 8146 - 8150
GARNER: "Advanced Drug Delivery Reviews", vol. 55, 2003, STANBERRY, UNIVERSITY PRESS, pages: 1497 - 1513
NEWCOMB ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 370, 2007, pages 633 - 642
KANG ET AL.: "Virology", vol. 312, 2003, STANBERRY, UNIVERSITY PRESS, pages: 233 - 244
KANG ET AL., VIROLOGY, vol. 312, 2003, pages 233 - 244
WYSOCKA ET AL., TRENDS IN BIOCHEMICAL SCIENCES, vol. 28, no. 6, 2003, pages 294 - 304
FATAHZADEH ET AL., AMERICAN ACADEMY OF DERMATOLOGY, vol. 6, no. 27, 2007, pages 737 - 763
BRADY ET AL., ANTIVIRAL RESEARCH, vol. 61, 2003, pages 73 - 81
MORFIN ET AL., JOURNAL OF CLINICAL VIROLOGY, vol. 26, 2002, pages 29 - 37
FROBERT ET AL., ANTIVIRAL RESEARCH., 2008, pages 7928 - 7936
LEBEL ET AL., JOURNAL OF CLINICAL VIROLOGY, vol. 37, 2006, pages 34 - 37
BRADY ET AL.: "Antiviral Research", vol. 61, 2003, STANBERRY, UNIVERSITY PRESS, pages: 73 - 81
SHARANGI, FOOD RESEARCH INTERNATIONAL, vol. 42, 2009, pages 5 - 6
PATERSON ET AL., SCIENCE, vol. 310, 2005, pages 451 - 453
WILLIAMSON ET AL., JOURNAL OF ALLERGY CLINICAL IMMUNOLOGY, vol. 118, 2006, pages 1369 - 1374
SONG ET AL., ANTIVIRUS RESPONSE, vol. 68, 2005, pages 66 - 74
HE ET AL., WORLD JOURNAL OF GASTROENTEROLOGY, vol. 17, no. 11, 2011, pages 1507 - 1514
ISAACS ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 3, 2008, pages 962 - 970
CHEN ET AL., JOURNAL OFZHEJIANG UNIVERSITY SCIENCE, vol. 6, 2003, pages 714 - 718
CHEN ET AL.: "Handbook of Green Tea and Health Research", 2009, NOVA SCIENCE PUBLISHERS, INC.
CHEN ET AL., JOURNAL OF ZHEJIANG UNIVERSITY SCIENCE, vol. 6, 2003, pages 714 - 718
"Martindale - The Complete Drug Reference", 1999, pages: 367 - 389
"Martindale - The Complete Drug Reference", 1999, pages: 112 - 270
"Handbook of Pharmaceutical Excipients", 2003, PHARMACEUTICAL PRESS
MATHIOWITZ ET AL., J. SCANNING MICROSCOPY, vol. 4, 1990, pages 329
BECK ET AL., FERTIL. STERIL., vol. 31, 1979, pages 545
BENITA ET AL., J. PHARM. SCI., vol. 73, 1984, pages 1721
MATHIOWITZ ET AL., REACTIVE POLYMERS, vol. 6, 1987, pages 275
SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING
ALLEN, T.M., CULLIS, P.R.: "Drug delivery systems: entering the mainstream", SCIENCE, vol. 303, no. 5665, 2004, pages 1818 - 22, XP002427419, DOI: doi:10.1126/science.1095833
"Introduction to Pharmaceutical Dosage Forms", 1985, LEA & FEBIGER
CHEN, DU, CHINESE J CHEM, vol. 21, 2003, pages 979 - 981
CHEN ET AL., J. CHROMATOGRAPHY, vol. 982, 2002, pages 163 - 165
BECHER, P.: "Encyclopedia of Emulsion Technology", 1983
ISAACS CE ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 3, 2008, pages 962 - 970
"DNeasy Blood and Tissue Handbook", 2006, QIAGEN
WILLIAMSON ET AL., J. OF ALLERGY CLINICAL IMMUNOLOGY, vol. 118, 2006, pages 1369 - 1374

Citation (search report)

[XI] DE 10156794 A1 20030612 - MEDIGENE AG [DE]
[Y] DAIKOKU, TOHRU ET AL: "Polyphenols including catechin from green tea with in vitro antiviral activity exhibited anti- herpes simplex virus activity but not anti-influenza virus activity in mice", JOURNAL OF TRADITIONAL MEDICINES, vol. 28, no. 2, 20 May 2011 (2011-05-20), pages 63 - 72, XP009154524
[Y] LAM W H ET AL: "A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG]", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 12, no. 21, 1 November 2004 (2004-11-01), pages 5587 - 5593, XP004588162, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2004.08.002
[Y] LANDIS-PIWOWAR KRISTIN R ET AL: "A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-ga llate as a potential anticancer agent", CANCER RESEARCH, vol. 67, no. 9, May 2007 (2007-05-01), pages 4303 - 4310, XP002664870, ISSN: 0008-5472
[Y] YU ZHIYONG ET AL: "Prodrugs of fluoro-substituted benzoates of EGC as tumor cellular proteasome inhibitors and apoptosis inducers.", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES JUN 2008 LNKD- PUBMED:19325839, vol. 9, no. 6, June 2008 (2008-06-01), pages 951 - 961, XP002664871, ISSN: 1422-0067
[I] UESATO S ET AL: "Inhibitory Effects of 3-O-Acyl-(+)-catechins on Epstein-Barr Virus Activation", CHEMICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, vol. 51, no. 12, 1 January 2003 (2003-01-01), pages 1448 - 1450, XP002999177, ISSN: 0009-2363, DOI: 10.1248/CPB.51.1448
[A] CHEN ET AL: "Isolation and purification of a novel long - chain acyl catechin from lipophilic tea polyphenols", CHINESE JOURNAL OF CHEMISTRY, ZHONGGUO KEXUEYUAN, CN, vol. 21, no. 7, 1 January 2003 (2003-01-01), pages 979 - 981, XP009075627, ISSN: 1001-604X
[A] MORI S ET AL: "Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O- gallate fatty acid monoester derivatives: Effect of alkyl chain length", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 14, 15 July 2008 (2008-07-15), pages 4249 - 4252, XP022852939, ISSN: 0960-894X, [retrieved on 20080210], DOI: 10.1016/J.BMCL.2008.02.020

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

EP 2543370 A1 20130109; BR 102012006217 A2 20131126; JP 2013014568 A 20130124

DOCDB simple family (application)

EP 11178325 A 20110822; BR 102012006217 A 20120320; JP 2011277686 A 20111219